AuntMinnie

(A) Free-response receiver operating characteristic (FROC) curve for DBT-DINO and DINOv2 (Meta AI) on the detection task. DINOv2 achieved higher sensitivity than DBT-DINO across most false-positive thresholds. (B) Detection rates of DBT-DINO and DINOv2 for lesions that were ultimately found to be benign (n = 70) and lesions that were found to be cancerous (n = 66). Error bars represent 95% CIs estimated via patient-level bootstrapping with 1000 repetitions. Both models showed similar detection rates for cancerous lesions, whereas DINOv2 detected more benign lesions than DBT-DINO. (C) Example bounding box predictions for DBT-DINO and DINOv2 on the detection test set. Each image is a single two-dimensional section from a three-dimensional digital breast tomosynthesis volume; the first column shows a mediolateral oblique view, and the second and third columns show craniocaudal views. Both models struggled to detect very small lesions, such as the 3-mm-diameter lesion shown in the first column. FP = false positive.

DBT-based foundational model classifies breast density

DBT-DINO showed strong performance in classifying breast density from DBT images.

Featured

Ai Head

Can LLMs fill the communication gap with referring clinicians?

Aneurysm

CT-selected thrombectomy shows 1-year benefit in large-core stroke

Liebel-Flarsheim recalls Optiray CT contrast agent

August 4, 2026

MRI-based AI model maps local brain aging

August 3, 2026

Curium to acquire Lantheus in $8 billion deal

August 3, 2026

A.) Rate of imaging utilization during surveillance by year, 2008 to 2022. B.) Rate of endoscopic ultrasound (EUS) and pancreatic surgery per 100 person years, 2008 to 2022.

Surveillance imaging doesn't improve pancreatic cancer survival

August 3, 2026

Podcast: Testing the effectiveness of today's MR safety standard of care

More episodes »

Check out our Cases of the Week!

60-year-old man with lesion on carcinoma follow-up revisited

A 60-year-old man presented for follow-up imaging at an outpatient imaging center. He had recently been diagnosed with tongue squamous cell carcinoma.

58-year-old woman with upper arm pain after a fall revisited

38-year-old woman with abdominal pain, missed period revisited

(A) Free-response receiver operating characteristic (FROC) curve for DBT-DINO and DINOv2 (Meta AI) on the detection task. DINOv2 achieved higher sensitivity than DBT-DINO across most false-positive thresholds. (B) Detection rates of DBT-DINO and DINOv2 for lesions that were ultimately found to be benign (n = 70) and lesions that were found to be cancerous (n = 66). Error bars represent 95% CIs estimated via patient-level bootstrapping with 1000 repetitions. Both models showed similar detection rates for cancerous lesions, whereas DINOv2 detected more benign lesions than DBT-DINO. (C) Example bounding box predictions for DBT-DINO and DINOv2 on the detection test set. Each image is a single two-dimensional section from a three-dimensional digital breast tomosynthesis volume; the first column shows a mediolateral oblique view, and the second and third columns show craniocaudal views. Both models struggled to detect very small lesions, such as the 3-mm-diameter lesion shown in the first column. FP = false positive.

DBT-based foundational model classifies breast density

CT-selected thrombectomy shows 1-year benefit in large-core stroke

MRI-based AI model maps local brain aging

Surveillance imaging doesn't improve pancreatic cancer survival

PET/MRI detects arterial inflammation in prostate cancer patients

Ai Head

Can LLMs fill the communication gap with referring clinicians?

DeepHealth lands FDA nod for breast ultrasound AI software

Radiologists can identify three out of four AI-generated images

Radiology dominates thirty years of FDA AI device approvals

Incorrect AI suggestions influence reader performance on mammography

Ct Contrast

Liebel-Flarsheim recalls Optiray CT contrast agent

Exo expands Iris handheld ultrasound with subscription-free option

GE HealthCare launches Logiq e compact ultrasound system family

MediView XR90 holographic navigation used for liver biopsy in Florida

Aycan launches AI anonymizer tool for medical imaging data

Tsuneo Imai

Canon Medical names Tsuneo Imai as president, CEO

Imai has more than 40 years of experience in the healthcare industry.

ED patients prefer empathetic communication for incidental findings

SNMMI issues analysis of 2027 HOPPS proposed rule

More Practice Management

Exo expands Iris handheld ultrasound with subscription-free option

By AuntMinnie.com staff writers

The option allows for scanning after a one-time activation without the need for cloud connectivity or ongoing software costs.

August 4, 2026

GE HealthCare launches Logiq e compact ultrasound system family

By AuntMinnie.com staff writers

The Logiq e X and Logiq e S systems are designed for point-of-care use across a variety of clinical settings.

August 4, 2026

MediView XR90 holographic navigation used for liver biopsy in Florida

By AuntMinnie.com staff writers

The procedure, a percutaneous liver mass biopsy, was performed to target a liver lesion approximately 10 cm deep.

August 4, 2026

MediView XR's clinical augmented reality and surgical navigation technology.

Aycan launches AI anonymizer tool for medical imaging data

By AuntMinnie.com staff writers

The tool anonymizes images during routing without requiring a separate workflow step.

August 4, 2026

Artificial Intelligence Ai Hand 400

Medara nets $400,000 NCI grant for AI breast cancer risk platform

By AuntMinnie.com staff writers

The platform combines longitudinal mammographic imaging with clinical risk factors to predict short-term breast cancer risk.

August 4, 2026

Research Money 400

Canon Medical names Tsuneo Imai as president, CEO

By AuntMinnie.com staff writers

Imai has more than 40 years of experience in the healthcare industry.

August 4, 2026

Trice Imaging expands to India

By AuntMinnie.com staff writers

Tricefy is a cloud platform supporting ultrasound, x-ray, mammography, and dual-energy x-ray absorptiometry workflows.

August 3, 2026

Imricor launches cardiac catheterization vertical

By AuntMinnie.com staff writers

The launch follows recent U.S. Food and Drug Administration (FDA) clearances for NorthStar and the Vision-MR Diagnostic Catheter.

August 3, 2026

Plus Therapeutics rebrands as Cerenome

By AuntMinnie.com staff writers

The move reflects the company's evolution from a therapeutics-focused organization into an integrated central nervous system (CNS) oncology company.

August 3, 2026

RevealDx secures distribution deal, $3.4M investment from 4DMedical

By AuntMinnie.com staff writers

Under the agreement, 4DMedical will distribute RevealAI-Lung in the U.S., Europe, Australia, and New Zealand.

August 3, 2026

GE HealthCare expands breast imaging portfolio

By AuntMinnie.com staff writers

The system expands the company's breast imaging portfolio with tools for supplemental screening of women with dense breasts and remote exam review.

August 3, 2026

GE HealthCare's new Invenia ABUS and ABUS StreamVue system.

Novartis secures expanded approval for Pluvicto

By AuntMinnie.com staff writers

Pluvicto can now be used as therapy in patients with PSMA-positive metastatic hormone-sensitive prostate cancer, in combination with an androgen receptor pathway inhibitor.

July 31, 2026

Prostate Imaging